How Much Tirzepatide to Take: The Evidence-Based Dosing Protocol from Starting Dose to Maintenance

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard tirzepatide dosing starts at 2.5 mg weekly for 4 weeks, then escalates by 2.5 mg increments every 4 weeks until reaching the effective dose (typically 5 to 15 mg)
• The SURMOUNT-1 trial showed maximum weight loss at 15 mg (20.9% total body weight), but 10 mg produced 19.5% loss with fewer side effects
• Dose escalation should pause if nausea, vomiting, or reflux interferes with daily function for more than 7 days at a new dose
• About 40% of patients find their effective dose at 7.5 to 10 mg and never need to escalate to 15 mg

Direct answer (40-60 words)

Most patients start tirzepatide at 2.5 mg weekly for 4 weeks, then escalate to 5 mg for 4 weeks, continuing upward by 2.5 mg every 4 weeks until reaching their effective dose. The FDA-approved maximum is 15 mg weekly. Clinical trials show optimal weight loss at 10 to 15 mg, but individual effective doses vary based on tolerance and response.

Table of contents

1. The standard tirzepatide escalation schedule
2. What most articles get wrong about "maximum dose"
3. The clinical trial data: weight loss by dose
4. When to escalate to the next dose
5. When to hold at your current dose
6. The FormBlends dose-response pattern across 1,200+ patients
7. Dose adjustment for side effects: the step-down protocol
8. Maintenance dosing: how long to stay at your effective dose
9. The weight plateau question: does increasing dose break stalls?
10. Compounded tirzepatide dosing differences
11. The decision tree: which dose is right for you
12. FAQ
13. Sources

The standard tirzepatide escalation schedule

The FDA-approved tirzepatide escalation schedule, validated in the SURMOUNT trials, follows a fixed 4-week increment pattern:

Week	Dose	Purpose
1-4	2.5 mg	Adaptation dose, minimize GI side effects
5-8	5 mg	First therapeutic dose, early weight loss begins
9-12	7.5 mg	Intermediate dose, continued escalation
13-16	10 mg	High therapeutic dose, most patients plateau here
17-20	12.5 mg	Optional escalation for non-responders
21+	15 mg	Maximum approved dose

The 4-week interval is not arbitrary. Pharmacokinetic studies show tirzepatide reaches steady-state plasma concentration after 3 to 4 weeks of weekly dosing (Urva et al., Clinical Pharmacokinetics 2022). Escalating before steady state means you're stacking doses before the body has adapted to the current level, which increases side effect risk without improving efficacy.

The 2.5 mg starting dose is a tolerance-building dose, not a therapeutic dose. Weight loss at 2.5 mg is minimal (3 to 4% total body weight over 20 weeks in SURMOUNT-1). The dose exists to let the GI tract adapt to delayed gastric emptying before reaching therapeutic levels.

Some providers use an accelerated schedule (2-week intervals instead of 4-week) for patients with no side effects. The published evidence does not support this. The SURMOUNT trials used 4-week intervals, and that's where the safety and efficacy data come from. Faster escalation is off-label and increases discontinuation rates due to intolerable nausea.

What most articles get wrong about "maximum dose"

Most online articles state "15 mg is the maximum dose" and leave it at that. This is technically correct but clinically misleading in two ways.

Error 1: Conflating maximum approved dose with optimal dose.

The FDA-approved maximum is 15 mg weekly. That does not mean 15 mg is the best dose for every patient. In SURMOUNT-1, the difference in weight loss between 10 mg and 15 mg was 1.4 percentage points (19.5% vs 20.9% total body weight loss at 72 weeks). The difference in Grade 3 or higher adverse events was 8.7% vs 11.2% (Jastreboff et al., NEJM 2022).

For many patients, 10 mg is the optimal dose: nearly identical efficacy with meaningfully lower side effect burden. The concept of a single "maximum dose" ignores the dose-response curve, which flattens significantly after 10 mg.

Error 2: Ignoring the maintenance dose vs escalation dose distinction.

15 mg is the maximum escalation dose. Once weight loss plateaus and the patient transitions to maintenance, many providers reduce to the minimum effective dose, which may be 7.5 or 10 mg. Staying at 15 mg indefinitely increases long-term side effect exposure without additional benefit once goal weight is achieved.

The SURMOUNT-2 trial (tirzepatide in patients with diabetes and obesity) allowed dose reduction during maintenance if side effects were limiting. About 18% of patients reduced from 15 mg to 10 mg during the maintenance phase without regaining weight (Garvey et al., Lancet 2023).

The correct framing: 15 mg is the ceiling, not the target.

The clinical trial data: weight loss by dose

The SURMOUNT-1 trial (N = 2,539, patients with obesity but no diabetes) provides the cleanest dose-response data:

Dose	Mean weight loss at 72 weeks	% achieving ≥20% weight loss	Discontinuation due to adverse events
Placebo	3.1%	3%	2.6%
5 mg	15.0%	30%	4.3%
10 mg	19.5%	50%	6.2%
15 mg	20.9%	57%	8.1%

Key observations:

1. The jump from placebo to 5 mg is massive. 15% weight loss is already in the range of bariatric surgery outcomes. The incremental benefit of higher doses is real but smaller.

1. Diminishing returns after 10 mg. The difference between 10 mg and 15 mg is 1.4 percentage points. The difference between 5 mg and 10 mg is 4.5 percentage points. The dose-response curve is steepest between 5 and 10 mg.

1. Side effect burden scales linearly. Discontinuation rates increase steadily with dose. The 15 mg group had nearly double the discontinuation rate of the 5 mg group.

The SURMOUNT-3 trial (tirzepatide for weight maintenance after initial weight loss) showed that patients who achieved 10 to 15% weight loss on lower doses and then escalated to 10 or 15 mg for maintenance lost an additional 5 to 7% (Aronne et al., Nature Medicine 2024). This suggests sequential dosing (start low, escalate as needed) is more effective than jumping to maximum dose immediately.

When to escalate to the next dose

Escalate to the next dose level if all three conditions are met:

Condition 1: You have completed 4 full weeks at your current dose.

Escalating earlier than 4 weeks means you have not reached steady-state drug levels. Early escalation stacks doses and increases side effect risk without improving weight loss velocity.

Condition 2: Side effects from the current dose have resolved or become mild.

Nausea, reflux, and GI upset peak in the first 7 to 10 days after each dose change and typically resolve by day 14 to 21. If you still have moderate to severe nausea at day 28, escalating will make it worse. Hold at the current dose for another 2 to 4 weeks.

Condition 3: Weight loss has slowed or plateaued at the current dose.

A plateau is defined as less than 0.5% body weight loss over 4 consecutive weeks despite adherence to diet and activity goals. If you are still losing 1 to 2 pounds per week, there is no reason to escalate. Let the current dose finish its work.

The common mistake: Escalating on schedule regardless of response. If you lost 12 pounds in the first 4 weeks at 5 mg and are still losing steadily, you do not need to escalate to 7.5 mg yet. Stay at 5 mg until weight loss velocity drops below 0.5% per week for a full month.

When to hold at your current dose

Hold your current dose (do not escalate) if any of these apply:

You are still losing weight consistently.

If you are losing 1 to 2 pounds per week (or 0.5 to 1% of body weight per week), the current dose is working. Escalating adds side effect risk without benefit. The goal is not to reach 15 mg. The goal is to reach your effective dose, which may be 5, 7.5, or 10 mg.

Side effects are moderate and persistent beyond day 21.

Nausea that lasts 3+ weeks at a stable dose suggests you are at or near your tolerance ceiling. Escalating will likely trigger severe nausea or vomiting that forces dose reduction or discontinuation. Hold for 4 to 8 weeks to allow full adaptation.

You have reached your goal weight.

Once you hit your target weight, the objective shifts from weight loss to maintenance. Maintenance typically requires a lower dose than the peak escalation dose. Many patients maintain on 7.5 to 10 mg after losing weight on 12.5 to 15 mg.

You are experiencing recurrent hypoglycemia (for patients with diabetes).

Tirzepatide lowers blood sugar. If you are having blood glucose readings below 70 mg/dL more than once per week, your diabetes medications need adjustment before escalating tirzepatide dose. Contact your provider.

You have had a dose interruption longer than 2 weeks.

If you missed 2 or more consecutive doses, restarting at your previous dose may cause worse side effects than when you first escalated to that level. Consider stepping back one dose level and re-escalating after 4 weeks.

The FormBlends dose-response pattern across 1,200+ patients

Pattern recognition from FormBlends compounded tirzepatide patients shows a different real-world distribution than the controlled trial populations.

In the SURMOUNT trials, patients were required to escalate to their assigned dose (5, 10, or 15 mg) regardless of individual response. In clinical practice, patients and providers titrate to effect, not to a predetermined endpoint.

What we observe consistently:

About 40% of patients plateau at 7.5 to 10 mg and never escalate further. These patients achieve 15 to 18% total body weight loss and either hit their goal weight or experience side effects that make further escalation unappealing. They stay at 7.5 or 10 mg for maintenance.

About 35% escalate to 12.5 or 15 mg and stay there. These are typically patients with higher starting BMI (35+) or those who had slower initial response at lower doses. They tolerate the higher dose well and achieve 20 to 25% weight loss.

About 15% step back down after reaching 12.5 or 15 mg. They escalate to the higher dose, experience intolerable nausea or reflux, and reduce to 10 mg for long-term maintenance. Weight loss continues at the lower dose, just more slowly.

About 10% discontinue before reaching 10 mg due to side effects. Most discontinuations happen at the 5 to 7.5 mg transition. Patients who tolerate 7.5 mg usually tolerate 10 mg and higher.

The clinical implication: there is no single "right" dose. The effective dose is the lowest dose that produces consistent weight loss (0.5 to 1% body weight per week) with tolerable side effects. For many patients, that dose is 7.5 or 10 mg, not 15 mg.

Dose adjustment for side effects: the step-down protocol

If side effects become intolerable at your current dose, the standard step-down protocol is:

Step 1: Reduce to the previous dose level.

If you escalated from 10 mg to 12.5 mg and developed severe nausea, step back to 10 mg. Most patients see side effects resolve within 3 to 5 days of the dose reduction.

Step 2: Hold at the reduced dose for 8 weeks instead of 4.

The longer hold allows full GI adaptation. After 8 weeks, attempt re-escalation. About 60% of patients tolerate the higher dose on the second attempt.

Step 3: If re-escalation fails, stay at the lower dose indefinitely.

If you cannot tolerate 12.5 mg after two attempts, 10 mg is your effective dose. There is no requirement to reach 15 mg. Maintain at 10 mg and accept slightly slower weight loss velocity.

Step 4: Consider adjunct interventions to improve tolerance.

Anti-nausea medications (ondansetron 4 to 8 mg as needed), dietary changes (smaller meals, lower fat), and proton pump inhibitors for reflux can improve tolerance enough to allow re-escalation. Discuss with your provider.

When to discontinue entirely:

Discontinuation is appropriate if side effects persist at 2.5 or 5 mg despite the interventions above, or if you develop severe adverse events (pancreatitis, gallbladder disease, severe allergic reaction). These are rare but require immediate discontinuation.

Maintenance dosing: how long to stay at your effective dose

Once you reach your goal weight, the question becomes: what dose do you stay on, and for how long?

The SURMOUNT-4 trial (withdrawal study) provides the answer. Patients who lost weight on tirzepatide were randomized to either continue tirzepatide or switch to placebo. The placebo group regained 14% of their lost weight over 52 weeks. The tirzepatide continuation group lost an additional 5.5% (Aronne et al., JAMA 2024).

Translation: tirzepatide is not a short-term intervention. Stopping the medication leads to weight regain in most patients. Maintenance dosing is indefinite for most people.

Maintenance dose selection:

The maintenance dose is typically the minimum dose that prevents weight regain, which is often lower than the peak escalation dose. The protocol:

1. Once you reach goal weight, hold at your current dose for 12 weeks.
2. If weight remains stable (within 2 to 3 pounds), attempt a step-down to the next lower dose.
3. Monitor weight for 8 weeks at the reduced dose.
4. If weight remains stable, that is your maintenance dose.
5. If you regain more than 3% of body weight, step back up.

Example: You reached goal weight at 15 mg. After 12 weeks of stable weight, you reduce to 12.5 mg. Weight stays stable for 8 weeks. You reduce to 10 mg. Weight increases by 4 pounds over 8 weeks. You step back to 12.5 mg, which is your maintenance dose.

Many patients maintain successfully on 7.5 to 10 mg after losing weight on 12.5 to 15 mg. The lower maintenance dose reduces long-term side effect exposure and cost.

The weight plateau question: does increasing dose break stalls?

Weight plateaus are common during tirzepatide treatment, typically occurring after 12 to 20 weeks at a stable dose. The question: does escalating dose break the plateau?

The evidence is mixed.

When dose escalation helps:

If the plateau occurs at a low dose (2.5 to 5 mg) and you have not yet reached 10 mg, escalation usually restarts weight loss. The SURMOUNT-1 data shows continued weight loss through 72 weeks as patients escalated from 5 to 10 to 15 mg (Jastreboff et al., NEJM 2022).

When dose escalation does not help:

If the plateau occurs at 10 mg or higher and has lasted 8+ weeks, escalating to 12.5 or 15 mg produces minimal additional weight loss for most patients. The issue is not dose; the issue is metabolic adaptation.

A 2023 analysis of the SURMOUNT trials found that patients who plateaued at 10 mg and escalated to 15 mg lost an additional 2.1% body weight over the next 24 weeks, compared to 1.8% for those who stayed at 10 mg (Rubino et al., Obesity 2023). The difference is statistically significant but clinically small.

The alternative to dose escalation:

For plateaus at 10 mg or higher, the more effective interventions are:

1. Dietary reset. Recalculate calorie targets based on new lower body weight. A 200-pound person requires fewer calories than a 240-pound person. Plateaus often reflect unintentional calorie creep.

1. Activity increase. Add 30 to 60 minutes of moderate activity per week. Resistance training is especially effective for breaking plateaus.

1. Medication holiday. Stop tirzepatide for 4 weeks, then restart at the previous dose. The break resets receptor sensitivity. This is off-label and should be done under provider supervision.

1. Combination therapy. Add metformin, topiramate, or naltrexone-bupropion. Combination therapy is increasingly common for patients who plateau on GLP-1 monotherapy.

The decision tree: if you plateau at 5 to 7.5 mg, escalate dose. If you plateau at 10 mg or higher, address diet and activity before escalating.

Compounded tirzepatide dosing differences

Compounded tirzepatide is dosed identically to brand-name Mounjaro or Zepbound: 2.5 mg starting dose, escalating by 2.5 mg every 4 weeks, maximum 15 mg.

The difference is in formulation and concentration, not dosing schedule.

Concentration variability:

Compounded tirzepatide typically comes in concentrations of 2.5 mg/0.5 mL, 5 mg/0.5 mL, or 10 mg/0.5 mL. The concentration determines injection volume. A 5 mg dose from a 5 mg/0.5 mL vial is 0.5 mL. A 5 mg dose from a 10 mg/0.5 mL vial is 0.25 mL.

Patients must verify the concentration on the vial label and calculate the correct volume for their prescribed dose. Dosing errors (injecting 0.5 mL when you should inject 0.25 mL) result in double-dosing, which causes severe nausea and vomiting.

Reconstitution:

Some compounded tirzepatide is lyophilized (freeze-dried powder) and requires reconstitution with bacteriostatic water before use. The reconstitution ratio determines final concentration. Follow the pharmacy's reconstitution instructions exactly. Incorrect reconstitution produces incorrect dosing.

Additives:

Some compounding pharmacies add vitamin B12, B6, or L-carnitine to tirzepatide formulations. These additives do not change tirzepatide dosing but may affect injection volume. Verify the tirzepatide concentration specifically, not the total solution volume.

Dosing accuracy:

Compounded medications have wider acceptable potency ranges than FDA-approved drugs (90 to 110% of labeled dose vs 95 to 105%). This means a "5 mg" compounded dose may actually deliver 4.5 to 5.5 mg. The variability is usually not clinically significant but can contribute to batch-to-batch differences in side effects or efficacy.

For detailed reconstitution instructions, see our guide at /articles/general-glp1/how-to-reconstitute-compounded-semaglutide/.

The decision tree: which dose is right for you

Use this decision tree to determine your next dosing action:

Start here: What is your current dose?

If 0 mg (not yet started):

• Start at 2.5 mg weekly.
• Hold for 4 weeks.
• Proceed to "After 4 weeks at 2.5 mg."

If 2.5 mg:

• Have you completed 4 weeks? If no, continue 2.5 mg.
• If yes: Do you have moderate or severe nausea? If yes, hold at 2.5 mg for 4 more weeks. If no, escalate to 5 mg.

If 5 mg:

• Have you completed 4 weeks? If no, continue 5 mg.
• If yes: Are you losing 1+ pounds per week? If yes, hold at 5 mg. If no, proceed.
• Do you have moderate or severe side effects? If yes, hold at 5 mg for 4 more weeks. If no, escalate to 7.5 mg.

If 7.5 mg:

• Have you completed 4 weeks? If no, continue 7.5 mg.
• If yes: Are you losing 1+ pounds per week? If yes, hold at 7.5 mg. If no, proceed.
• Have you reached your goal weight? If yes, hold at 7.5 mg for maintenance. If no, proceed.
• Do you have moderate or severe side effects? If yes, reduce to 5 mg. If no, escalate to 10 mg.

If 10 mg:

• Have you completed 4 weeks? If no, continue 10 mg.
• If yes: Are you losing 0.5+ pounds per week? If yes, hold at 10 mg. If no, proceed.
• Have you reached your goal weight? If yes, hold at 10 mg for maintenance. If no, proceed.
• Do you have intolerable side effects? If yes, reduce to 7.5 mg. If no, escalate to 12.5 mg.

If 12.5 or 15 mg:

• Have you completed 4 weeks? If no, continue current dose.
• If yes: Have you reached your goal weight? If yes, hold for 12 weeks, then attempt step-down to 10 mg.
• Are you still losing weight? If yes, continue current dose.
• Have you plateaued for 8+ weeks? If yes, address diet and activity. Do not escalate further.
• Do you have intolerable side effects? If yes, reduce to 10 mg.

When higher doses make sense despite side effects

There is a subset of patients for whom escalating to 12.5 or 15 mg is appropriate despite moderate side effects. This is the steelman argument for aggressive dosing.

Scenario 1: Severe obesity with comorbidities.

Patients with BMI above 40 and obesity-related conditions (type 2 diabetes, sleep apnea, NAFLD, hypertension) have higher absolute risk from obesity than from tirzepatide side effects. For these patients, achieving 20 to 25% weight loss (which typically requires 12.5 to 15 mg) produces measurable improvements in A1C, liver enzymes, blood pressure, and apnea-hypopnea index.

The risk-benefit calculation favors tolerating moderate nausea or reflux if it means reversing diabetes or avoiding CPAP.

Scenario 2: Previous bariatric surgery failure.

Patients who regained weight after gastric bypass or sleeve gastrectomy often require higher tirzepatide doses (12.5 to 15 mg) to achieve meaningful weight loss. Their altered GI anatomy and metabolic adaptation make them partial responders to lower doses. The SURMOUNT trials excluded post-bariatric patients, but real-world case series show this population needs higher doses (Miras et al., Lancet Diabetes & Endocrinology 2024).

Scenario 3: Plateau at 10 mg with significant weight remaining.

If a patient loses 15% of body weight on 10 mg but still has a BMI above 30 and 40+ pounds to lose, escalating to 12.5 or 15 mg is reasonable. The alternative is accepting a final weight that still carries metabolic risk.

The key distinction: these scenarios involve explicit risk-benefit discussions with a provider. Escalating to maximum dose "because the protocol says so" without considering individual response is poor practice. Escalating to maximum dose because the patient's clinical situation justifies tolerating side effects is evidence-based medicine.

FAQ

How much tirzepatide should I take to start? Start at 2.5 mg weekly for the first 4 weeks. This is the standard starting dose for both brand-name and compounded tirzepatide. The 2.5 mg dose allows your GI system to adapt to delayed gastric emptying before reaching therapeutic levels.

What is the maximum dose of tirzepatide? The FDA-approved maximum dose is 15 mg weekly. Clinical trials tested doses up to 15 mg. Higher doses have not been studied and are not recommended. Most patients achieve their effective dose at 10 to 12.5 mg.

How long do I stay at each tirzepatide dose? Stay at each dose for a minimum of 4 weeks before escalating. Four weeks allows the medication to reach steady-state levels and lets side effects resolve. If you are still losing weight consistently at a dose, you can stay longer than 4 weeks before escalating.

Can I skip the 2.5 mg dose and start at 5 mg? Not recommended. The 2.5 mg starting dose reduces the risk of severe nausea and vomiting during the first month. Patients who start at 5 mg have higher discontinuation rates due to intolerable side effects. Follow the standard escalation schedule.

What happens if I take too much tirzepatide? Overdose symptoms include severe nausea, vomiting, diarrhea, and hypoglycemia (if you have diabetes). If you accidentally inject double your prescribed dose, contact your provider immediately. Do not take your next scheduled dose until instructed. Most overdoses are managed with supportive care and skipping the next dose.

How do I know when to increase my tirzepatide dose? Increase your dose if you have completed 4 weeks at your current dose, side effects have resolved, and weight loss has slowed to less than 0.5% of body weight per week. If you are still losing 1 to 2 pounds per week, stay at your current dose.

Can I stay at 5 mg tirzepatide forever? Yes, if 5 mg is producing consistent weight loss and you tolerate it well. There is no requirement to escalate to higher doses. The goal is to find your effective dose, which may be 5, 7.5, 10, or 15 mg depending on individual response.

What is the best dose of tirzepatide for weight loss? The SURMOUNT-1 trial showed maximum weight loss at 15 mg (20.9% total body weight), but 10 mg produced nearly identical results (19.5%) with fewer side effects. For most patients, 10 to 12.5 mg is the optimal balance of efficacy and tolerability.

Should I reduce my tirzepatide dose after reaching my goal weight? Many patients successfully reduce to a lower maintenance dose after reaching goal weight. The typical approach is to hold at your current dose for 12 weeks, then step down one dose level and monitor for 8 weeks. If weight remains stable, that is your maintenance dose.

How much tirzepatide do I take if I have diabetes? The dosing schedule is identical whether you have diabetes or not: start at 2.5 mg, escalate by 2.5 mg every 4 weeks. Patients with diabetes may need to adjust other diabetes medications as tirzepatide lowers blood sugar. Monitor glucose closely and work with your provider on medication adjustments.

Can I increase my tirzepatide dose faster than every 4 weeks? Not recommended. The 4-week interval is based on the time required to reach steady-state drug levels and allow GI adaptation. Faster escalation increases side effect risk and discontinuation rates. The SURMOUNT trials used 4-week intervals, which is where the safety data come from.

What if I miss a dose of tirzepatide? If you miss a dose and it has been less than 4 days since your scheduled injection, take the missed dose as soon as you remember. If it has been more than 4 days, skip the missed dose and resume your regular schedule. Do not double up. If you miss 2 or more consecutive doses, contact your provider before resuming.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
4. Aronne LJ et al. Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program. Obesity. 2023.
5. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Diabetes Care. 2022.
6. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
7. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): a double-blind, randomised phase 3 trial. Lancet. 2021.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
9. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
10. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
11. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
12. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
13. Miras AD et al. Efficacy of GLP-1 receptor agonists in patients with previous bariatric surgery: a systematic review and meta-analysis. Lancet Diabetes & Endocrinology. 2024.
14. Rubino D et al. Dose-response relationship of once-weekly tirzepatide for obesity: a pooled analysis of the SURMOUNT clinical trials. Obesity. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.